Table 1.
Studies comparing STW 5 and prokinetics
| Medicinal products studied | Study type | Study characteristics | Jadad score of trial quality | HMP with RCTs in FD and IBS | Ref |
|---|---|---|---|---|---|
| STW 5, metoclopramide | Randomized controlled, single blind study in FGID | Multicenter single-blinded clinical trial in 77 patients with functional gastroenteropathy. Metoclopramide liquid vs. STW 5 liquid, 2 weeks. End points: GI symptoms including fullness, stomach cramps and heartburn; tolerability | 2 | Yesa | [3] |
| STW 5, metoclopramide | Retrospective epidemiological cohort study in FD | Multicenter, retrospective, pharmacoepidemiological cohort study in 961 patients with functional dyspepsia. End points: Number of symptom free patients after treatment, days of inability to work | n.a. | Yesa | [4] |
| STW 5, STW 5-II, cisapride | Double-blind, randomized controlled clinical trial in FD | Randomized controlled clinical trial in 183 patients with dysmotility type of functional dyspepsia. Double-dummy design. 4 weeks treatment, 6 months follow-up. End point: gastrointestinal symptom score (GIS) [5] | 5 | Yesa | [6] |
| Combination of peppermint and caraway oil, cisapride | Double-blind, randomized controlled clinical trial in FD | Randomized controlled clinical trial in 120 patients with functional dyspepsia. Double-dummy design. 4 weeks treatment. End point: pain score | 5 | No | [31] |
| Rikkunshito, domperidone | Open, randomized trial in FD | Open clinical trial in 27 patients over 4 weeks. End point gastrointestinal symptom rating scale (GSRS) | 2 | No | [32] |
| Hewei xiaopi capsules, domperidone | Open, randomized trial in FD | Open clinical trial in 63 patients over 4 weeks. End point: FD symptoms | 1 | No | [33] |
| Sinisan (modified), cisapride | Open, randomized trial, IBS | Open clinical trial in 47 patients over 8 weeks. End point: IBS symptom scoring | 1 | No | [34] |
a For STW 5 only, RCS supporting both efficacy in FD and IBS and post marketing surveillance safety are data published [10]. Jadad score [35] for clinical trials: ≥3 good quality; n.a. not applicable, MCP metoclopramide, HMP herbal medicinal product, FD functional dysfunction, IBS irritable bowel syndrome